General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-01 | 2024-09 | -0.75 | N/A | N/A | N/A |
2024-08-07 | 2024-06 | -0.69 | -0.82 | -0.13 | -18.84% |
2024-05-08 | 2024-03 | -0.63 | -0.76 | -0.13 | -20.63% |
2024-02-28 | 2023-12 | -0.52 | -0.23 | 0.29 | 55.77% |
2023-11-03 | 2023-09 | -0.64 | -0.55 | 0.09 | 14.06% |
2023-08-02 | 2023-06 | -0.76 | -0.56 | 0.2 | 26.32% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-17 | JP Morgan | Upgrade | Underweight | Neutral |
2023-10-16 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-09-28 | Stifel | Upgrade | Hold | Buy |
2023-09-12 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-02 | Oppenheimer | Upgrade | Perform | Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-07-24 | BURKLY LINDA | Officer | 73.14K | Sale |
2023-12-04 | EATON BRUCE E | Chairman of the Board | 74.79K | Sale |
2024-05-12 | HOPFIELD JESSICA | Director | 67.70K | Purchase |
2024-05-19 | LUCERA ERICK J. | Chief Financial Officer | 116.83K | Sale |
2024-09-03 | MEI BAISONG | Officer | 133.90K | Sale |
2021-12-21 | MICHAELS LISA ANNE | Officer | 22.68K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 8.17M | 67.20M | 10.00% |
2023-06-29 | Blackrock Inc. | 7.60M | 62.51M | 9.30% |
2023-06-29 | State Street Corporation | 6.64M | 54.66M | 8.14% |
2023-06-29 | Deep Track Capital, Lp | 3.45M | 28.42M | 4.23% |
2023-06-29 | Avidity Partners Management, LP | 3.00M | 24.69M | 3.68% |
2023-06-29 | Marshall Wace LLP | 2.84M | 23.36M | 3.48% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 4.85M | 43.18M | 5.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.49M | 20.51M | 3.05% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.10M | 17.25M | 2.57% |
2023-08-30 | iShares Russell 2000 ETF | 1.60M | 14.28M | 1.96% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.16M | 9.57M | 1.42% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.01M | 8.32M | 1.24% |
8.31 first target
Stifel analyst Dae Gon Ha upgraded Editas Medicine (NASDAQ: EDIT) from Hold to Buy with a price target of $17.00 (from $9.00).
The analyst comments "We are upgrading EDIT shares to Buy and increasing TP to $17 (vs. $9 previously). We think EDIT-301's (sickle cell disease [SCD]) progress has received minimal credit from investors. But with YE23 goal to dose n=20, in addition to important regulatory insights expected from exa-cel (CRSP, covered by Stifel colleague Ben Burnett), we think EDIT-301 deserves a fresh look. Within, we discuss the disconnect between EDIT and CRSP valuations - at comparable time points in development, EDIT-301's clinical profile thus far (vs. exa-cel), our optimism - both clinically and regulatory - in EDIT-301's strategy (i.e., HBG1/2 promoter region), market receptivity - and TAM - for follow-on gene editing like EDIT-301, and potential upside from the IP dispute.
$EDIT suck my dick Cathy Wood 🪵
Bitch, dumb as a bag of rocks
$EDIT stay away from this garbage and Kathy Woods retarded ass advice!
Morgan Stanley is a typical wire house research outfit… late to the party
why can’t I access ark holdings pdf?
have they sold them all?
Oh Brian did your short position get you fucked in the ass?
$EDIT I’m not selling I bought more today